Clarifying False Online Information

 

The Company has recently become aware that the website of RCPFARMA contains false statements purporting a partnership with the Company, which may mislead investors and the public. The Company hereby solemnly clarifies that such claims are entirely unfounded. The Company has never engaged in any form of collaboration discussions with RCPFARMA, and all information published on its website regarding the Company is factually incorrect.

The Company adheres strictly to the principles of openness and transparency in its disclosures. All material matters—including but not limited to clinical trial progress, product development, strategic collaborations, licensing transactions, and other significant corporate events—are formally announced through the Market Observation Post System (MOPS) and the Company’s official website, in full compliance with applicable laws and regulations. This ensures that all investors receive consistent, timely, and accurate information.

Investors and the general public are urged to exercise caution when verifying any partnership information not officially released by the Company or through its authorized channels. They should not rely on or disseminate unverified content, and are advised to safeguard their own interests by referring solely to official announcements.

Caliway Biopharmaceuticals remains committed to the highest standards of rigor and transparency, and will continue to deliver innovative therapeutic solutions that surpass existing treatment outcomes for patients worldwide. We shall respond to the expectations of society and the market with tangible progress and results.